ResultsIQ

ResultsIQ › Latest results › Alkem Laboratories Limited

Alkem Laboratories Limited Q4 FY25 results deck summary

NSE: ALKEM · BSE: 539523

Results deck of 29 May 2025, summarised by AI from the filing.

Alkem Q4FY25 revenue ₹31,438 million, up 7.1% YoY; FY25 EBITDA margin 19.4% vs 17.7% in FY24.

Key takeaways

  1. Q4 revenue Q4FY25 total revenue from operations ₹31,438 million, up 7.1% YoY, with India sales ₹21,355 million up 8.1%.
  2. FY25 EBITDA FY25 EBITDA ₹25,122 million with margin 19.4% vs 17.7% in FY24; EBITDA increased 11.9% YoY.
  3. Q4 margin Q4FY25 EBITDA margin fell to 12.4% from 13.7% in Q4FY24, with EBITDA de-growing 2.7% YoY.
  4. Growth driver Non-US business grew around 28.2% YoY in Q4FY25, fuelled by double-digit growth in Australia and key European markets.
  5. US weakness US business de-grew 2.5% in Q4FY25 and 10.4% in FY25.

Original filing on BSE

Alkem Laboratories Limited Q1 FY27 results

As filed: Revenue ₹3,740 cr (+11% year on year), EBITDA ₹766 cr (+4% year on year), PAT ₹521 cr (−22% year on year), EBITDA margin 20.5% (−147 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹3,603 cr (+15% year on year), EBITDA ₹517 cr (+33% year on year), PAT ₹251 cr (+41% year on year), EBITDA margin 14.4% (+195 bps). Score 59 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit before exceptional items growth were above it. EBITDA margin rose 195 bps year on year. Other income 47% of PBT. Tax rate 40%. Revenue fell 4% from last quarter. Share price after the results: −0.5% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹3,737 cr (+11% year on year), EBITDA ₹828 cr (+9% year on year), PAT ₹653 cr (+2% year on year), EBITDA margin 22.2% (−34 bps). Score 47 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 34 bps year on year. Revenue fell 7% from last quarter. Share price after the results: −8.8% in 28 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹4,001 cr (+17% year on year), EBITDA ₹921 cr (+22% year on year), PAT ₹779 cr (+11% year on year), EBITDA margin 23.0% (+97 bps). Score 62 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 97 bps year on year. Tax rate 13%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Share price after the results: −2.4% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹3,371 cr (+11% year on year), EBITDA ₹740 cr (+22% year on year), PAT ₹668 cr (+21% year on year), EBITDA margin 22.0% (+190 bps). Score 57 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 190 bps year on year. Tax rate 13%. Share price after the results: +11.3% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹3,144 cr (+7% year on year), EBITDA ₹390 cr (−3% year on year), PAT ₹322 cr (+6% year on year), EBITDA margin 12.4% (−129 bps). Score 35 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 129 bps year on year. Other income 37% of PBT. Revenue fell 7% from last quarter. Share price after the results: −6.8% in 29 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹3,374 cr (+2% year on year), EBITDA ₹759 cr (+7% year on year), PAT ₹641 cr (+6% year on year), EBITDA margin 22.5% (+123 bps). Score 33 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 123 bps year on year. Tax rate 12%. Profit fell 9% from last quarter.
  • Q2 FY25: Revenue ₹3,415 cr (−1% year on year), EBITDA ₹753 cr (+1% year on year), PAT ₹702 cr (+14% year on year), EBITDA margin 22.1% (+33 bps). Score 34 of 100, Below trend. EBITDA margin rose 33 bps year on year. Tax rate 10%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Alkem Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.